Sapna Gangaputra, MD
Ophthalmology · Nashville, TNNPI 1124387709
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 50.2% of the total. Reporting peaked in 2023 at $283 and has fallen 60.0% since, to $113 in 2024. That places this record below the midpoint for ophthalmology clinicians in TN, where the typical reported total is $1,443.
Across 11 payments — averaging $40.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$225
- Genentech, Inc.$90
- Alimera Sciences, Inc.$57
- AbbVie$53
- Biogen$24
Across 2 payments — averaging $9373.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$19K
What the payments were for
- Food & beverage$448100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 3 | $225 |
| Genentech, Inc. | 2 | $90 |
| Alimera Sciences, Inc. | 3 | $57 |
| AbbVie | 2 | $53 |
| Biogen | 1 | $24 |
How this compares
$448 in reported general payments places this provider in the 25th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 102 | $688,079 |
| Mycophenolate Mofetil | 13 | $3,866 |
| Cyclosporine | 17 | $3,746 |
| ValacyclovirValacyclovir Hcl | 53 | $2,197 |
| Prednisolone Acetate | 25 | $1,164 |
| MethotrexateMethotrexate Sodium | 47 | $953 |
| Prednisone | 85 | $610 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $439 |
| Latanoprost | 19 | $211 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 17 | $180 |
| Brimonidine Tartrate | 17 | $75 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Nashville
- Deborah ShermanNashville$3M
- Brian BiesmanNashville$630K
- Edward ChaumNashville$158K
- Jeffrey HornNashville$106K
- Avni FinnNashville$57K
- Louise MawnNashville$56K
- Jeffrey KammerNashville$30K
- Gary JerkinsNashville$15K
- Allison SmithNashville$13K
- Christine ShiehNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.